ANAPTYSBIO, INC. Cash and Restricted Cash
ANAPTYSBIO, INC. (ANAB) had Cash and Restricted Cash of $133.83 million as of 2026-06-30, per its 10-KT filed 2026-09-21.
Financial Statements › Cash Flow › Cash
us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents · last filed 2026-09-21
- 2026-06-30: Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents $133.83M.
- 2026-03-31: Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents $248.47M.
- 2025-12-31: Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents $138.20M; Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents as first filed $238.20M.
- 2025-09-30: Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents $109.83M.
| Period end | Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents | Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents as first filed |
|---|---|---|
| 2026-06-30 | $133.83M 10-KT · filed 2026-09-21 | |
| 2026-03-31 | $248.47M 10-Q · filed 2026-05-12 | |
| 2025-12-31 | $138.20M 10-KT · filed 2026-09-21 | $238.20M 10-K · filed 2026-03-03 |
| 2025-09-30 | $109.83M 10-Q · filed 2025-11-04 | |
| 2025-06-30 | $0.00 10-KT · filed 2026-09-21 | $44.30M 10-Q · filed 2025-08-06 |
| 2025-03-31 | $98.64M 10-Q · filed 2026-05-12 | |
| 2024-12-31 | $23.08M 10-KT · filed 2026-09-21 | $123.08M 10-K · filed 2025-02-27 |
| 2024-09-30 | $191.58M 10-Q · filed 2025-11-04 | |
| 2024-06-30 | $71.82M 10-Q · filed 2025-08-06 | |
| 2024-03-31 | $53.70M 10-Q · filed 2025-05-05 | |
| 2023-12-31 | $0.00 10-KT · filed 2026-09-21 | $35.97M 10-K · filed 2024-03-11 |
| 2023-09-30 | $26.30M 10-Q · filed 2024-11-05 | |
| 2023-06-30 | $35.21M 10-Q · filed 2024-08-05 | |
| 2023-03-31 | $94.56M 10-Q · filed 2024-05-09 | |
| 2022-12-31 | $71.31M 10-K · filed 2026-03-03 | |
| 2022-09-30 | $58.55M 10-Q · filed 2023-11-02 | |
| 2022-06-30 | $71.70M 10-Q · filed 2023-08-07 | |
| 2022-03-31 | $166.41M 10-Q · filed 2023-05-11 | |
| 2021-12-31 | $495.73M 10-K · filed 2025-02-27 | |
| 2021-09-30 | $336.39M 10-Q · filed 2022-11-08 | |
| 2021-06-30 | $332.31M 10-Q · filed 2022-08-08 | |
| 2021-03-31 | $284.21M 10-Q · filed 2022-05-04 | |
| 2020-12-31 | $250.52M 10-K · filed 2024-03-11 | |
| 2020-09-30 | $209.21M 10-Q · filed 2021-11-04 | |
| 2020-06-30 | $221.23M 10-Q · filed 2021-08-09 | |
| 2020-03-31 | $165.38M 10-Q · filed 2021-05-04 | |
| 2019-12-31 | $171.08M 10-K · filed 2023-03-01 | |
| 2019-09-30 | $182.96M 10-Q · filed 2020-11-04 | |
| 2019-06-30 | $146.61M 10-Q · filed 2020-08-10 | |
| 2019-03-31 | $105.91M 10-Q · filed 2020-05-06 | |
| 2018-12-31 | $113.66M 10-K · filed 2022-03-07 | |
| 2018-09-30 | $293.47M 10-Q · filed 2019-11-08 | |
| 2018-06-30 | $57.12M 10-Q · filed 2019-08-08 | |
| 2018-03-31 | $69.53M 10-Q · filed 2019-05-07 | |
| 2017-12-31 | $81.25M 10-K · filed 2021-02-25 | |
| 2017-09-30 | $26.73M 10-Q · filed 2018-11-08 | |
| 2017-06-30 | $30.81M 10-Q · filed 2018-08-07 | |
| 2017-03-31 | $96.81M 10-Q · filed 2018-05-08 | |
| 2016-12-31 | $51.29M 10-K · filed 2020-03-02 | |
| 2016-09-30 | $47.19M 10-Q · filed 2017-11-07 | |
| 2016-06-30 | $50.65M 10-Q · filed 2017-08-10 | |
| 2015-12-31 | $51.74M 10-K · filed 2019-02-28 | |
| 2014-12-31 | $22.27M 10-K · filed 2018-03-05 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Kailera Therapeutics, Inc. (KLRA) | United States | $1.552B | |
| Innoviva, Inc. (INVA) | United States | $1.493B | 4.62 |
| Syndax Pharmaceuticals Inc (SNDX) | United States | $1.606B | -8.82 |
| ArriVent BioPharma, Inc. (AVBP) | United States | $1.485B | -10.25 |
| Rapport Therapeutics, Inc. (RAPP) | United States | $1.623B | -14.56 |
| Stoke Therapeutics, Inc. (STOK) | United States | $1.630B | -9.82 |
| Xeris Biopharma Holdings, Inc. (XERS) | United States | $1.632B | -80.10 |
| Ultragenyx Pharmaceutical Inc. (RARE) | United States | $1.456B | -5.62 |
| OMEROS CORP (OMER) | United States | $1.456B | 5.50 |
| Eton Pharmaceuticals, Inc. (ETON) | United States | $1.701B | 80.74 |